The HPV vaccine works by training your immune system to recognize and block human papillomavirus before it can infect your cells. It does this using protein shells that look almost identical to the real virus but contain no viral DNA, so they can’t cause infection. Your body produces antibodies against these shells, and those antibodies stand ready to neutralize the actual virus if you’re ever exposed.
What’s Actually in the Vaccine
The key ingredient is something called a virus-like particle, or VLP. Scientists take the main protein that forms the outer shell of HPV (called L1) and produce it in yeast cells. When manufactured, these L1 proteins spontaneously assemble into hollow spheres that are structurally and visually almost identical to real HPV. The critical difference: they’re empty inside. There’s no genetic material, no ability to replicate, and no way to cause an HPV infection.
The current vaccine used in the U.S., Gardasil 9, contains VLPs representing nine different HPV types. Seven of those (types 16, 18, 31, 33, 45, 52, and 58) are high-risk strains responsible for cervical, anal, throat, vulvar, and vaginal cancers. The other two (types 6 and 11) cause genital warts. A small amount of aluminum salt is also included. Aluminum has been used in vaccines since the 1930s and helps provoke a stronger immune response, essentially acting as a signal flare that draws your immune system’s attention to the VLPs.
How Your Immune System Responds
When the vaccine is injected into your upper arm, your immune system encounters the VLPs and treats them like an actual threat. Immune cells engulf the particles, break them down, and present fragments to other immune cells that specialize in producing antibodies. These antibodies are custom-shaped to latch onto the surface of HPV’s outer shell.
The process also creates memory cells that persist long-term. If real HPV enters your body months or years later, these memory cells rapidly produce a flood of antibodies, neutralizing the virus before it gains a foothold. This is why the vaccine is preventive rather than therapeutic: it arms your immune system in advance, but it can’t clear an infection that’s already established.
How Antibodies Block the Virus
HPV normally infects you by attaching to the surface of skin or mucosal cells, getting pulled inside, and then hijacking the cell’s machinery to replicate. Vaccine-induced antibodies disrupt this process at multiple points. Some antibodies physically block the virus from attaching to cells in the first place by covering the specific sites on HPV’s shell that it uses to grip onto cell surfaces. Others allow the virus to land on a cell but then prevent it from being absorbed inside, essentially trapping it on the surface where it’s harmless and eventually cleared away.
This layered defense is part of what makes the vaccine so effective. Even if one antibody doesn’t catch the virus at the first step, another can stop it at the next.
How Well It Works
The real-world results are striking. A large Swedish study covering 2006 through 2017 found a nearly 90% reduction in cervical cancer incidence among girls vaccinated before age 17, compared to unvaccinated women. Even when researchers adjusted for other factors influencing cancer risk across all age groups, vaccination was associated with a 63% reduced risk of cervical cancer diagnosis.
The impact extends well beyond cancer. Among young adult women in the U.S., infections with the HPV types that cause most cancers and genital warts have dropped 81% since the vaccine was introduced. That decline happened within roughly a decade of widespread vaccination, faster than many public health experts initially expected.
Dosing Schedule by Age
How many shots you need depends on when you start. For those beginning vaccination between ages 9 and 14, the schedule is two doses spaced 6 to 12 months apart. Starting at age 15 or older requires three doses: the first, then a second at 1 to 2 months, and a third at 6 months. People with weakened immune systems also follow the three-dose schedule regardless of age.
The reason younger recipients need fewer doses is that their immune systems mount a stronger antibody response to each shot. Two doses in a 12-year-old produce antibody levels comparable to three doses in a 20-year-old.
Why It’s Given Before Sexual Activity
The vaccine is most effective when given before any exposure to HPV, which is why routine vaccination is recommended at age 11 or 12. HPV is extremely common. Most sexually active people encounter at least one strain at some point, and infections can happen with the very first sexual contact. Vaccinating early ensures the immune system is fully prepared before any exposure occurs.
That said, the vaccine still offers real protection to people who have already been sexually active. It guards against any of the nine targeted strains you haven’t yet encountered. Clinical trials confirmed that the vaccine works against HPV types a person isn’t already infected with at the time of vaccination, even if they’ve been exposed to other strains.
Vaccination for Adults 27 to 45
In 2018, the FDA expanded approval of Gardasil 9 to adults through age 45. In clinical trials involving women aged 27 to 45, the vaccine showed 87.7% efficacy against persistent infection and precancerous lesions from the targeted HPV types. Over 99% of women in this age group developed antibodies to all nine vaccine strains, with immune responses comparable to younger women.
The recommendation for this age group, however, is more individualized. Most adults in their 30s and 40s have already been exposed to common HPV strains, so the added benefit is smaller on a population level. The CDC recommends shared decision-making between patient and provider for this group, meaning it’s worth discussing based on your personal risk factors rather than being a blanket recommendation. No HPV testing or screening is required before getting vaccinated.
What the Vaccine Does Not Do
The vaccine prevents new infections but does not treat existing ones. If you already have an active HPV infection or HPV-related cell changes, the vaccine won’t clear them. It also doesn’t cover all HPV types. There are over 200 strains of HPV, and Gardasil 9 targets nine. Those nine, however, account for the vast majority of HPV-related cancers and genital warts, which is why the vaccine’s real-world impact has been so large despite not covering every strain.
Routine cervical cancer screening remains important even for vaccinated individuals, since a small percentage of cervical cancers are caused by HPV types not included in the vaccine.